COLOMBO, NICOLETTA

COLOMBO, NICOLETTA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 452 (tempo di esecuzione: 0.047 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial 01 - Articolo su rivista 2025 Colombo, Nicoletta +
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial 01 - Articolo su rivista 2025 Colombo N. +
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease 01 - Articolo su rivista 2025 Colombo, Nicoletta +
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety 01 - Articolo su rivista 2025 Colombo N. +
External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer 01 - Articolo su rivista 2025 Gaeta, AFumagalli, DColombo, N +
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer 01 - Articolo su rivista 2025 Colombo N. +
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics 01 - Articolo su rivista 2025 Colombo, Nicoletta +
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer 01 - Articolo su rivista 2025 Colombo, Nicoletta +
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial 01 - Articolo su rivista 2025 Colombo, Nicoletta +
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results 01 - Articolo su rivista 2025 Colombo N. +
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status: Clinical Studies 01 - Articolo su rivista 2025 Colombo N. +
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study 01 - Articolo su rivista 2025 Colombo N. +
Predictors of recurrence in early-stage cervical cancer without adjuvant treatment after radical surgery 01 - Articolo su rivista 2025 Colombo, Nicoletta +
Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer 01 - Articolo su rivista 2025 Colombo N. +
Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer 01 - Articolo su rivista 2025 Colombo N. +
Systems epigenetic approach towards non-invasive breast cancer detection 01 - Articolo su rivista 2025 Colombo N. +
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) 01 - Articolo su rivista 2024 Colombo N. +
A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety 01 - Articolo su rivista 2024 Colombo, Nicoletta +
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 01 - Articolo su rivista 2024 Colombo N.Lissoni A. A. +
Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial 01 - Articolo su rivista 2024 Colombo N. +